SAN DIEGO–(BUSINESS WIRE)–Acadia Prescribed drugs Inc. (Nasdaq: ACAD) right now introduced that it’ll take part in a fireplace chat on the Canaccord Genuity forty fourth Annual Development Convention on Wednesday, August 14, 2024 at 10:00 a.m. Japanese Time.
A dwell webcast of Acadia’s hearth chat can be accessible on the corporate’s web site, Acadia.com, beneath the traders part and an archived recording can be accessible on the web site for roughly one month following the presentation.
About Acadia Prescribed drugs
Acadia is advancing breakthroughs in neuroscience to raise life. For 30 years we’ve been working on the forefront of healthcare to deliver very important options to individuals who want them most. We developed and commercialized the primary and solely FDA-approved drug to deal with hallucinations and delusions related to Parkinson’s illness psychosis and the primary and solely FDA-approved drug for the therapy of Rett syndrome. Our clinical-stage growth efforts are centered on Prader-Willi syndrome, Alzheimer’s illness psychosis and a number of different packages focusing on neuropsychiatric signs in central nervous system issues. For extra data, go to us at Acadia.com and observe us on LinkedIn and Twitter.
View supply model on businesswire.com: https://www.businesswire.com/information/dwelling/20240807578775/en/
Investor Contact:
Acadia Prescribed drugs Inc.
Al Kildani
(858) 261-2872
[email protected]
Acadia Prescribed drugs Inc.
Jessica Tieszen
(858) 261-2950
[email protected]
Supply: Acadia Prescribed drugs Inc.
